Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
GRI Bio, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee equal to 7.0% of the gross proceeds (effective 2024-02-01).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- A.G.P./Alliance Global Partners
- Value
- cash fee equal to 7.0% of the gross proceeds
- Effective
- 2024-02-01
Exact text from the filing
On February 1, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which A.G.P. agreed to act as exclusive placement agent for the issuance and sale of the Shares and Warrants.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
GRI Bio, Inc. entered into Securities Purchase Agreement with each purchaser identified on the signature pages thereto valued at combined purchase price of $1.10 (effective 2024-02-01).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- each purchaser identified on the signature pages thereto
- Value
- combined purchase price of $1.10
- Effective
- 2024-02-01
Exact text from the filing
On February 1, 2024, GRI Bio, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement with each purchaser identified on the signature pages thereto (the “Purchase Agreement”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), (i) 330,450 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) 4,669,550 pre-funded warrants (the “Pre-Funded Warrants”) exercisable for an aggregate of 4,669,550 shares of Common Stock, (iii) 5,000,000 Series B-1 common warrants (the “Series B-1 Common Warrants”) exercisable for an aggregate of 5,000,000 shares of Common Stock, and (iv) 5,000,000 Series B-2 common warrants (the “Series B-2 Common Warrants,” and together with the Series B-1 Common Warrants, the “Common Warrants”) exercisable for an aggregate of 5,000,000 shares of Common Stock.
View on SEC.gov